Here’€™s why the MCC is reviewing nevirapine (Part 2)
Living with AIDS Programme 92

It is because of the absence of these documents that the manufacturers of nevirapine ‘€“ Boehringer-Ingelheim ‘€“ withdrew their application for registration of the drug for PMTCT use in the US. Currently, the sponsors of the HIVNET 012 study in Uganda – the National Institutes of Health ‘€“ have returned to that country in an effort to collate the missing documents. In this report, Khopotso Bodibe of Health-e News Service, attempts to piece together why the Uganda study is under review.

To obtain the audio file please contact the Editor.

Author

Free to Share

Creative Commons License

Republish our articles for free, online or in print, under a Creative Commons license.


Stay in the loop

We love that you love visiting our site. Our content is free, but to continue reading, please register.

Newsletter Subscription

Enable Notifications OK No thanks